Pharmacokinetics, Safety, and Tolerability of Cedirogant in Healthy Japanese and Chinese Adults.

Autor: Mohamed, Mohamed‐Eslam F, Qian, Yuli, D'Cunha, Ronilda, Hao, Shuai, Carcereri De Prati, Roberto, Levy, Gweneth F, Hew, Kinjal, Liu, Wei

Publikováno v: Clinical Pharmacology in Drug Development; Jul2024, Vol. 13 Issue 7, p801-809, 9p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis.

Autor: Mohamed MF; Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA., Qian Y; Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA., D'Cunha R; Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA., Sligh T; Velocity Clinical Research, North Hollywood, California, USA., Ferris LK; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Eldred A; Immunology Development, AbbVie Inc., North Chicago, Illinois, USA., Levy GF; Pharmacovigilance and Patient Safety, AbbVie Inc., North Chicago, Illinois, USA., Hao S; Discovery and Exploratory Statistics, AbbVie Inc., North Chicago, Illinois, USA., Gannu S; Regulated Bioanalysis, AbbVie Inc., North Chicago, Illinois, USA., Rizzo DG; Regulated Bioanalysis, AbbVie Inc., North Chicago, Illinois, USA., Liu W; Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA., Jazayeri S; Alliance Dermatology and Mohs Center, Phoenix, Arizona, USA., Sofen H; University of California Los Angeles School of Medicine and Dermatology Research Associates, Los Angeles, California, USA., Carcereri De Prati R; Immunology Development, AbbVie, Ludwigshafen, Germany.

Publikováno v: Clinical and translational science [Clin Transl Sci] 2024 Jan; Vol. 17 (1), pp. e13682. Date of Electronic Publication: 2023 Dec 19.